What Happened
- India's pharmaceutical exports grew 9.4% in FY2024-25 to reach $30.47 billion, crossing the $30 billion mark for the first time, according to data released by the Ministry of Commerce and Industry
- The United States remained the largest market for Indian pharma exports at 34% of total, followed by Europe at 19%
- The industry is targeting double-digit export growth in FY2026-27 (not FY2026), with the domestic market and export market combined projected to reach $130 billion by 2030 from a current base of ~$60 billion
- The Biopharma SHAKTI initiative — a government scheme to boost India's position in the global biopharmaceuticals market — is expected to further accelerate export growth in the medium term
- Active Pharmaceutical Ingredients (APIs) and formulations were the key growth drivers in FY25; vaccines and biologics are the emerging growth segments
- India's pharma sector remains structurally critical: it is the world's third-largest by production volume, the largest supplier of generic medicines globally (20% of global supply), and provides ~57% of APIs on the WHO prequalified list
Static Topic Bridges
India's Pharmaceutical Industry: Global Position and Domestic Structure
India is the world's third-largest pharmaceutical producer by volume (behind China and the US) and ranks 11th by value. With more than 3,000 pharmaceutical companies and 10,500 manufacturing units, India is home to the largest number of US FDA-approved plants outside the United States. The industry is a critical source of affordable medicines for the world — India supplies ~20% of global generic drugs and is often described as the "pharmacy of the world."
- Global ranking: 3rd by volume, 11th by value
- Number of companies: 3,000+; manufacturing units: 10,500+
- US FDA-approved plants in India: largest number outside the US
- Generics market share: ~20% of global generic drug supply
- WHO prequalified API supply: ~57% sourced from India
- Vaccine supply: ~60% of UNICEF's vaccine requirements; 90% of WHO measles vaccine demand
- Domestic market size: ~$60 billion (FY2025); target $130 billion by 2030
- Key pharma clusters: Hyderabad (bulk drugs/APIs), Ahmedabad (formulations), Mumbai (formulations/biotech), Baddi (formulations)
Connection to this news: India's $30.47 billion in pharma exports in FY25 is underpinned by a deep manufacturing base of FDA-approved and WHO-prequalified plants, enabling India to serve regulated markets (US, Europe) with certified quality generics at scale.
Generic Drugs and India's API Ecosystem
Active Pharmaceutical Ingredients (APIs) are the chemically active compounds that make medicines effective; formulations are the finished drug products (tablets, capsules, injectables). India's API industry supplies building blocks for both domestic formulations and global generics manufacturers. India's API production is concentrated in Hyderabad's Patancheru-Bollaram cluster, Ankleshwar and Panoli (Gujarat), and Visakhapatnam. A key strategic vulnerability: India is significantly dependent on China for key starting materials (KSMs) and certain APIs, particularly for antibiotics (65-70% of KSMs from China).
- API contribution to India's pharma exports (FY2025): significant share alongside formulations
- India's API import dependency on China: ~65-70% of Key Starting Materials (KSMs) for several critical APIs
- Policy response: PLI scheme for bulk drugs (APIs): Rs 6,940 crore outlay; 41 products across 136 applications
- Bulk Drug Parks scheme: 3 parks approved (Himachal Pradesh, Andhra Pradesh, Gujarat) for API manufacturing clusters
- WHO prequalified API supply from India: ~57% — critical for global vaccine and generics manufacturing
- US FDA imports from India (FY2025): ~$12–13 billion — largest single pharma export line
Connection to this news: The 9.4% growth in pharma exports masks an underlying structural challenge — India's API supply chain has Chinese input dependencies that create geopolitical and supply chain risk. The PLI for bulk drugs and Bulk Drug Parks are India's strategic response to reduce this vulnerability.
Pharma Regulation, CDSCO, and Export Quality Standards
India's pharmaceutical exports must meet the drug regulatory standards of destination countries. Domestically, the Central Drugs Standard Control Organisation (CDSCO) — under the Ministry of Health and Family Welfare — is the national regulatory authority, equivalent to the US FDA or European EMA. CDSCO approves new drugs, sets quality standards, and oversees clinical trials under the Drugs and Cosmetics Act, 1940. For exports, Indian plants undergo inspections and approvals by foreign regulators — US FDA, UK MHRA, WHO, EMA — creating a complex multi-regulator compliance environment.
- CDSCO: India's national drug regulatory authority under Ministry of Health; governs under Drugs and Cosmetics Act, 1940
- New Drugs and Clinical Trials Rules, 2019: updated framework for clinical trial regulation
- US FDA inspections in India: periodic; Warning Letters and Import Alerts can disrupt exports
- WHO Prequalification Programme: allows Indian manufacturers to supply medicines to UN procurement agencies and developing countries
- India's pharma export quality incidents: several US FDA import alerts (2010-2018) damaged reputation; sector has since significantly upgraded compliance
- Biopharma SHAKTI: new government initiative to boost biopharmaceuticals (biologics, biosimilars, vaccines) competitiveness
Connection to this news: India's pharma exports to regulated markets (US at 34%, Europe at 19%) depend entirely on maintaining foreign regulatory approvals — the sector's double-digit growth ambition is therefore contingent on zero regulatory failures and continued investment in quality compliance infrastructure.
Key Facts & Data
- Pharma exports (FY2024-25): $30.47 billion — up 9.4%; first time crossing $30 billion
- US share of pharma exports: 34%; Europe: 19%
- Double-digit growth target: FY2026-27
- India's pharma domestic + export market: ~$60 billion (target: $130 billion by 2030)
- Global ranking: 3rd by volume, 11th by value
- Generic drug supply: ~20% of global supply
- WHO prequalified API supply: ~57% from India
- UNICEF vaccine supply: ~60% from India
- PLI scheme for bulk drugs: Rs 6,940 crore outlay
- CDSCO: national drug regulator under Drugs and Cosmetics Act, 1940
- Number of manufacturing units: 10,500+; US FDA-approved plants: largest outside US